ERBB2 and breast cancer: These were applied by oncologists in the outcome prediction and management of BC patients by using different therapeutic regimens, such as chemotherapy, endocrinotherapy, and HER-2 targeted therapy.[4] However, as patients with histologically similar tumors at the same sub-types and clinical stage may have different clinical outcomes,[5] it remains difficult to predict patient survival.